Potassium channels in pulmonary arterial hypertension

European Respiratory Journal

Volumn 46, Issue 4, 2015, Pages 1167-1177

  Boucherat, Olivier ^a   Chabot, Sophie ^a   Antigny, Fabrice ^a,b   Perros, Frédéric ^a,b   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYCLOSPORIN A; FLUOXETINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; PHOSPHOLIPASE C; PLUMBAGIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; PROTEIN KCNK3; PROTEIN KINASE C; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; KCNA5 PROTEIN, HUMAN; NERVE PROTEIN; POTASSIUM CHANNEL SUBFAMILY K MEMBER 3; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

CELL DEATH; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE ASSOCIATION; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; KCNA5 GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN TARGETING; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ANIMAL; DISEASE COURSE; GENETIC PREDISPOSITION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; THROMBOSIS; VASOCONSTRICTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DEATH; CELL PROLIFERATION; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; KV1.5 POTASSIUM CHANNEL; MICRORNAS; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; PULMONARY ARTERY; SIGNAL TRANSDUCTION; THROMBOSIS; VASOCONSTRICTION;

EID: 84943236265     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00798-2015     Document Type: Conference Paper

References (93)

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D34-D41.
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl., 13S-24S.
3. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: Suppl., S10-S19.
4. Krick S, Platoshyn O, Sweeney M, et al. Activation of K+ channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C970-C979.
5. Krick S, Platoshyn O, Sweeney M, et al. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2002; 282: H184-H193.
6. Brevnova EE, Platoshyn O, Zhang S, et al. Overexpression of human KCNA5 increases IK V and enhances apoptosis. Am J Physiol Cell Physiol 2004; 287: C715-C722.
7. Krick S, Platoshyn O, McDaniel SS, et al. Augmented K+ currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. Am J Physiol Lung Cell Mol Physiol 2001; 281: L887-L894.
8. Ekhterae D, Platoshyn O, Krick S, et al. Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 281: C157-C165.
9. Kuhr FK, Smith KA, Song MY, et al. New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling. Am J Physiol Heart Circ Physiol 2012; 302: H1546-H1562.
10. Post JM, Hume JR, Archer SL, et al. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262: C882-C890.
11. Yuan XJ. Voltage-gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ Res 1995; 77: 370-378.
12. Pongs O, Schwarz JR. Ancillary subunits associated with voltage-dependent K+ channels. Physiol Rev 2010; 90: 755-796.
13. Post JM, Gelband CH, Hume JR. [Ca2+]i inhibition of K+ channels in canine pulmonary artery. Novel mechanism for hypoxia-induced membrane depolarization. Circ Res 1995; 77: 131-139.
14. Archer SL, Wu XC, Thébaud B, et al. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 2004; 95: 308-318.
15. Wang J, Juhaszova M, Rubin LJ, et al. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997; 100: 2347-2353.
16. Yuan XJ, Wang J, Juhaszova M, et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351: 726-727.
17. McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004; 95: 830-840.
18. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006; 113: 2630-2641.
19. Guignabert C, Tu L, Izikki M, et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α-targeted overexpression of the serotonin transporter. FASEB J 2009; 23: 4135-4147.
20. Pozeg ZI, Michelakis ED, McMurtry MS, et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003; 107: 2037-2044.
21. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
22. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
23. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168: 487-493.
24. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819.
25. Sato K, Webb S, Tucker A, et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992; 145: 793-797.
26. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
27. Eddahibi S, Guignabert C, Barlier-Mur AM, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006; 113: 1857-1864.
28. Guignabert C, Izikki M, Tu LI, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006; 98: 1323-1330.
29. Wang J, Juhaszova M, Conte JV Jr, et al. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet 1998; 352: 290.
30. Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220.
31. Cogolludo A, Moreno L, Lodi F, et al. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 2006; 98: 931-938.
32. Masson J, Sagné C, Hamon M, et al. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 1999; 51: 439-464.
33. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003; 4: 517-529.
34. Sverdlov M, Shajahan AN, Minshall RD. Tyrosine phosphorylation-dependence of caveolae-mediated endocytosis. J Cell Mol Med 2007; 11: 1239-1250.
35. Holmes TC, Fadool DA, Ren R, et al. Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain. Science 1996; 274: 2089-2091.
36. Nesti E, Everill B, Morielli AD. Endocytosis as a mechanism for tyrosine kinase-dependent suppression of a voltage-gated potassium channel. Mol Biol Cell 2004; 15: 4073-4088.
37. Choi WS, Khurana A, Mathur R, et al. Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res 2005; 97: 363-371.
38. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
39. Cogolludo A, Moreno L, Bosca L, et al. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circ Res 2003; 93: 656-663.
40. Moreno L, Frazziano G, Cogolludo A, et al. Role of protein kinase Czeta and its adaptor protein p62 in voltage-gated potassium channel modulation in pulmonary arteries. Mol Pharmacol 2007; 72: 1301-1309.
41. Gong J, Xu J, Bezanilla M, et al. Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2. Science 1999; 285: 1565-1569.
42. Timpe LC, Fantl WJ. Modulation of a voltage-activated potassium channel by peptide growth factor receptors. J Neurosci 1994; 14: 1195-1201.
43. Izikki M, Guignabert C, Fadel E, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009; 119: 512-523.
44. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
45. International PPH Consortium, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
46. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
47. West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94: 1109-1114.
48. Young KA, Ivester C, West J, et al. BMP signaling controls PASMC KV channel expression in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2006; 290: L841-L848.
49. Fantozzi I, Platoshyn O, Wong AH, et al. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 291: L993-L1004.
50. Zhang S, Fantozzi I, Tigno DD, et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-L754.
51. Waypa GB, Schumacker PT. Hypoxic pulmonary vasoconstriction: redox events in oxygen sensing. J Appl Physiol (1985) 2005; 98: 404-414.
52. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012; 185: 260-266.
53. Archer SL, Gomberg-Maitland M, Maitland ML, et al. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008; 294: H570-H578.
54. Shou J, Jing J, Xie J, et al. Nuclear factor of activated T cells in cancer development and treatment. Cancer Lett 2015; 361: 174-184.
55. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104: 11418-11423.
56. Yu Y, Platoshyn O, Zhang J, et al. c-Jun decreases voltage-gated K+ channel activity in pulmonary artery smooth muscle cells. Circulation 2001; 104: 1557-1563.
57. Hassoun PM. Inflammation in pulmonary arterial hypertension: is it time to quell the fire? Eur Respir J 2014; 43: 685-688.
58. Cohen-Kaminsky S, Hautefort A, Price L, et al. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today 2014; 19: 1251-1256.
59. Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011; 89: 771-783.
60. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 2012; 1: 223-233.
61. Courboulin A, Tremblay VL, Barrier M, et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011; 12: 128.
62. Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123: 1205-1215.
63. Remillard CV, Tigno DD, Platoshyn O, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 2007; 292: C1837-C1853.
64. Wipff J, Dieudé P, Guedj M, et al. Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum 2010; 62: 3093-3100.
65. Fountain SJ, Cheong A, Li J, et al. KV1.5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress. Am J Physiol Heart Circ Physiol 2007; 293: H2719-H2725.
66. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015; 15: 321-333.
67. White K, Loscalzo J, Chan SY. Holding our breath: the emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ 2012; 2: 278-290.
68. Meloche J, Pflieger A, Vaillancourt M, et al. miRNAs in PAH: biomarker, therapeutic target or both? Drug Discov Today 2014; 19: 1264-1269.
69. Ayon R, Pohl N, Yamamura A, et al. miRNA-29b directly downregulates K+ channel expression and function in IPAH-PASMC. FASEB J 2015; 29: Suppl., 662.16.
70. Zhang L, Foster K, Li Q, et al. S-acylation regulates Kv1.5 channel surface expression. Am J Physiol Cell Physiol 2007; 293: C152-C161.
71. Jindal HK, Folco EJ, Liu GX, et al. Posttranslational modification of voltage-dependent potassium channel Kv1.5: COOH-terminal palmitoylation modulates its biological properties. Am J Physiol Heart Circ Physiol 2008; 294: H2012-H2021.
72. Schwetz TA, Norring SA, Bennett ES. N-glycans modulate KV1.5 gating but have no effect on KV1.4 gating. Biochim Biophys Acta 2010; 1798: 367-375.
73. Benson MD, Li QJ, Kieckhafer K, et al. SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci USA 2007; 104: 1805-1810.
74. Boehmer C, Laufer J, Jeyaraj S, et al. Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol Biochem 2008; 22: 591-600.
75. Svoboda LK, Reddie KG, Zhang L, et al. Redox-sensitive sulfenic acid modification regulates surface expression of the cardiovascular voltage-gated potassium channel Kv1.5. Circ Res 2012; 111: 842-853.
76. Metallo CM, Vander Heiden MG. Metabolism strikes back: metabolic flux regulates cell signaling. Genes Dev 2010; 24: 2717-2722.
77. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res 2014; 115: 148-164.
78. González C, Baez-Nieto D, Valencia I, et al. K+ channels: function-structural overview. Compr Physiol 2012; 2: 2087-2149.
79. Gurney AM, Osipenko ON, MacMillan D, et al. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003; 93: 957-964.
80. Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006; 98: 1072-1080.
81. Tang B, Li Y, Nagaraj C, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009; 41: 476-483.
82. Nagaraj C, Tang B, Bálint Z, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.
83. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
84. Talley EM, Lei Q, Sirois JE, et al. TASK-1, a two-pore domain K+ channel, is modulated by multiple neurotransmitters in motoneurons. Neuron 2000; 25: 399-410.
85. Lauritzen I, Zanzouri M, Honoré E, et al. K+-dependent cerebellar granule neuron apoptosis. Role of task leak K+ channels. J Biol Chem 2003; 278: 32068-32076.
86. Pandit LM, Lloyd EE, Reynolds JO, et al. TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process. Hypertension 2014; 64: 1260-1265.
87. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954; 30: 195-207.
88. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl., D13-D21.
89. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369: 351-361.
90. Manoury B, Lamalle C, Oliveira R, et al. Contractile and electrophysiological properties of pulmonary artery smooth muscle are not altered in TASK-1 knockout mice. J Physiol 2011; 589: 3231-3246.
91. Zhai FG, Zhang XH, Wang HL. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 2009; 36: 850-856.
92. Courboulin A, Barrier M, Perreault T, et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 2012; 40: 618-629.
93. Fan Z, Liu B, Zhang S, et al. YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels. Clin Exp Hypertens 2015; 37: 381-387.